Dataset Information

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[¹⁸F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

ABSTRACT:

Purpose

2-[¹⁸F]FDG PET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies.

Methods

A literature review was performed, followed by a discussion between a multidisciplinary team of experts in the different fields involved in the RT planning of lung cancer, in order to guide clinical management. The project was led by experts of the two nuclear medicine societies (EANM and SNMMI) and radiation oncology (ESTRO).

Results and conclusion

This guideline results from a joint and dynamic collaboration between the relevant disciplines for this topic. It provides a worldwide, state of the art, and multidisciplinary guide to 2-[¹⁸F]FDG PET/CT RT planning in NSCLC and SCLC. These practical recommendations describe applicable updates for existing clinical practices, highlight potential flaws, and provide solutions to overcome these as well. Finally, the recent developments considered for future application are also reviewed.

SUBMITTER: Vaz SC

PROVIDER: S-EPMC8921015 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[<sup>18</sup>F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

Vaz Sofia C SC Adam Judit A JA Delgado Bolton Roberto C RC Vera Pierre P van Elmpt Wouter W Herrmann Ken K Hicks Rodney J RJ Lievens Yolande Y Santos Andrea A Schöder Heiko H Dubray Bernard B Visvikis Dimitris D Troost Esther G C EGC de Geus-Oei Lioe-Fee LF

European journal of nuclear medicine and molecular imaging 20220113 4

<h4>Purpose</h4>2-[<sup>18</sup>F]FDG PET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies.<h4>Methods</h4>A literature review was performed, f ...[more]

PMID: 35022844

Similar Datasets

Project description:BackgroundThere is no consensus regarding the clinical target volume (CTV) margins in radiotherapy for glioma. In this study, we aimed to perform a complete macropathologic analysis examining microscopic tumor extension (ME) to more accurately define the CTV in glioma.MethodsThirty-eight supra-total resection specimens of glioma patients were examined on histologic sections. The ME distance, defined as the maximum linear distance from the tumor border to the invasive tumor cells, was measured at each section. We defined the CTV based on the relationships between ME distance and clinicopathologic features.ResultsBetween February 2016 and July 2020, a total of 814 slides were examined, corresponding to 162 slides for low-grade glioma (LGG) and 652 slides for high-grade glioma (HGG). The ME value was 0.69 ± 0.43 cm for LGG and 1.29 ± 0.54 cm for HGG (P < 0.001). After multivariate analysis, tumor grade, O6-methylguanine-DNA-methyltransferase promoter methylated status (MGMTm), isocitrate dehydrogenase wild-type status (IDHwt), and 1p/19q non-co-deleted status (non-codel) were positively correlated with ME distance (all P < 0.05). We defined the CTV of glioma based on tumor grade. To take into account approximately 95% of the ME, a margin of 1.00 cm, 1.50 cm, and 2.00 cm were chosen for grade II, grade III, and grade IV glioma, respectively. Paired analysis of molecularly defined patients confirmed that tumors that had all three molecular alterations (i.e., MGMTm/IDHwt/non-codel) were the most aggressive subgroups (all P < 0.05). For these patients, the margin could be up to 1.50 cm, 2.00 cm, and 2.50 cm for grade II, grade III, and grade IV glioma, respectively, to cover the subclinical lesions in 95% of cases.ConclusionsThe ME was different between the grades of gliomas. It may be reasonable to recommend 1.00 cm, 1.50 cm, and 2.00 cm CTV margins for grade II, grade III, and grade IV glioma, respectively. Considering the highly aggressive nature of MGMTm/IDHwt/non-codel tumors, for these patients, the margin could be further expanded by 0.5 cm. These recommendations would encompass microscopic disease extension in 95% of cases.Trial registrationThe trial was registered with Chinese Clinical Trial Registry ( ChiCTR2100049376 ).

Dataset Information

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[¹⁸F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

Purpose

Methods

Results and conclusion

Publications

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[<sup>18</sup>F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

Purpose

Methods

Results and conclusion

Publications

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[<sup>18</sup>F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[¹⁸F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.